Time for radioimmunotherapy: an overview to bring improvements in clinical practice
-
O. Leaman Alcibar [5] ; D. Candini [1] ; F. López-Campos [1] ; M. Albert Antequera [6] ; V. Morillo Macías [2] ; A. J. Conde [7] ; A. Rodríguez Pérez [3] ; A. Hervás Morón [1] ; J. Contreras Martínez [8] ; C. Ferrer Albiach [2] ; S. Navarro Aguilar [9] ; M. E. Rodríguez-Ruiz [4]
-
[1] Hospital Ramón y Cajal
Hospital Ramón y Cajal
Madrid, España
-
[2] Hospital General de Castellón
Hospital General de Castellón
Castellón, España
-
[3] Hospital Ruber Internacional
Hospital Ruber Internacional
Madrid, España
-
[4] Clínica Universitaria de Navarra
Clínica Universitaria de Navarra
Pamplona, España
-
[5] Hospital Central de la Defensa Gómez Ulla
-
[6] Hospital Universitario La Ribera
-
[7] Hospital Universitario y Politécnico La Fe
-
[8] Hospital de Málaga
-
[9] Clínica Ricardo Palma. Perú
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 8 (August), 2019, págs. 992-1004
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Harnessing the patient’s own immune system against an established cancer has proven to be a successful strategy. Within the last years, several antibodies blocking critical “checkpoints” that control the activation of T cells, the immune cells able to kill cancer cells, have been approved for the use in patients with different tumours. Unfortunately, these cases remain a minority. Over the last years, radiotherapy has been reported as a means to turn a patient’s own tumour into an in situ vaccine and generate anti-tumour T cells in patients who lack sufficient anti-tumour immunity. Indeed, review data show that the strategy of blocking multiple selected immune inhibitory targets in combination with radiotherapy has the potential to unleash powerful anti-tumour responses and improve the outcome of metastatic solid tumours. Here, we review the principal tumours where research in this field has led to new knowledge and where radioimmunotherapy becomes a reality.
